LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

This study has been completed.
Sponsor:
Collaborator:
Unilever R&D
Information provided by:
Wageningen University
ClinicalTrials.gov Identifier:
NCT00167869
First received: September 12, 2005
Last updated: May 23, 2008
Last verified: May 2008
  Purpose

Hypertension is an increasingly important medical and public health issue. Literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. Recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. LACTOPRES is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.


Condition Intervention Phase
Hypertension
Behavioral: dairy peptides
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

Resource links provided by NLM:


Further study details as provided by Wageningen University:

Primary Outcome Measures:
  • Blood pressure

Estimated Enrollment: 135
Study Start Date: June 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • systolic blood pressure >= 140 mmHg
  • BMI between 18 and 32 kg/m2
  • apparently healthy

Exclusion Criteria:

  • antihypertensive medication
  • medically prescribed or slimming diet
  • lactating, pregnant
  • irregular pulse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167869

Locations
Netherlands
Wageningen University, Division of Human Nutrition
Wageningen, Netherlands, 6700 EV
Sponsors and Collaborators
Wageningen University
Unilever R&D
Investigators
Principal Investigator: Frans J Kok, PhD Wageningen University - Division of Human Nutrition
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00167869     History of Changes
Other Study ID Numbers: METC-WU 04/04
Study First Received: September 12, 2005
Last Updated: May 23, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Wageningen University:
hypertension
blood pressure
dairy peptides
bioactive peptides
randomized controlled trial

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 23, 2014